Skip to main content

Table 5 Tumour characteristics of HCC cases according to TNF-ɑ polymorphism

From: Association of IL-10 and TNF-α polymorphisms with risk and aggressiveness of hepatocellular carcinoma in patients with HCV-related cirrhosis

  

Genotype

Test of significance

 

Total, n = 73(%)

GG

GA

AA

Portal vein

 Thrombosed

10

10 (28.6)

0 (0.0)

0 (0.0)

MC

P = 0.002*

 Patent

63

25 (71.4)

22 (100.0)

16 (100.0)

Spleen

 Splenectomy

2

0 (0.0)

2 (9.1)

0(0.0)

MC

P = 0.313

 Mild

26

14 (40.0)

8 (36.4)

4(25.0)

 Moderate

39

18 (51.4)

12 (54.5)

9(56.2)

 Marked

6

2 (5.7)

2 (9.1)

2(12.5)

Ascites

 Negative

62

26 (74.3)

22 (100.0)

14 (87.5)

MC

P = 0.029*

 Positive

11

9 (25.7)

0 (0.0)

2 (12.5)

Lymph node

 Negative

64

28 (80.0)

22 (100.0)

14 (87.5)

MC

P = 0.08

 Positive

9

7 (20.0)

0 (0.0)

2 (12.5)

BCLC

 A

11

0 (0.0)

5 (22.7)

6 (37.5)

MC

P < 0.001*

 B

24

2 (5.7)

15 (68.2)

7 (43.8)

 C

24

19 (54.3)

2 (9.1)

3 (18.8)

 D

14

14 (40.0)

0 (0.00)

0 (0.0)

Site of lesion

 Right lobe

25

12 (34.3)

9 (40.9)

4 (25.0)

MC

P = 0.74

 Left lobe

12

7 (20.0)

2 (9.1)

3 (18.8)

 Multifocal

36

16 (45.7)

11 (50.0)

9 (56.2)

AGI

 A

22

0 (0.0)

12 (54.5)

10 (62.5)

MC

P < 0.001*

 B

23

9 (25.7)

8 (36.4)

6 (37.5)

 C

28

26 (74.3)

2 (9.1)

0 (0.0)

  1. * means statistically significant